As reported, the atraumatic tip of a 5f mynx control vascular closure device (vcd) did not enter the sheath.Therefore, the product wasn¿t available and manual compression was performed for 20 minutes and "recovered".There were no reports of patient injury.The sheath was not kinked or bent upon removal.There was no excessive force applied during insertion.The patient¿s bmi was not greater than 40 kg/m2.The mynx control vcd was prepared and used in accordance with the instructions for use (ifu).The mynx vcd was used in a percutaneous transluminal angioplasty (pta).There were no visible signs of device/package damage prior to use.The physician achieved certification on the use of mynx and has used the device several times prior to this procedure.The procedure used a retrograde approach.The femoral artery¿s suitability was verified on angiography, including the insertion angle (30~45 degrees) of the vascular sheath introducer.The vessel diameter was verified to be greater than 5mm in diameter.There was mild presence of pvd / calcium in the vicinity of the puncture site.The access site vessel was not tortuous.There was no stent near the puncture site.The vessel did not have stenosis >50% at the puncture site.The target femoral site was not previously closed with any closure less than 30 days prior to this procedure.There was no evidence of pre-existing hematoma, arteriovenous fistula, or pseudoaneurysm at the access site prior to use mynx control.The device will be returned for evaluation.Addendum: on product evaluation the sealant was found partially exposed from the sealant sleeves.
|
Complaint conclusion: as reported, the atraumatic tip of a 5f mynx control vascular closure device (vcd) did not enter the sheath.Therefore, the product wasn¿t available and manual compression was performed for 20 minutes and "recovered".There were no reports of patient injury.The sheath was not kinked or bent upon removal.There was no excessive force applied during insertion.The patient¿s body mass index (bmi) was not greater than 40 kg/m2.The mynx control vcd was prepared and used in accordance with the instructions for use (ifu).The mynx vcd was used in a percutaneous transluminal angioplasty (pta).There were no visible signs of device/package damage prior to use.The physician achieved certification on the use of mynx and has used the device several times prior to this procedure.The procedure used a retrograde approach.The femoral artery¿s suitability was verified on angiography, including the insertion angle (30-45 degrees) of the vascular sheath introducer.The vessel diameter was verified to be greater than 5mm in diameter.There was mild presence of peripheral vascular disease (pvd)/calcium in the vicinity of the puncture site.The access site vessel was not tortuous.There was no stent near the puncture site.The vessel did not have stenosis >50% at the puncture site.The target femoral site was not previously closed with any closure less than 30 days prior to this procedure.There was no evidence of pre-existing hematoma, arteriovenous fistula, or pseudoaneurysm at the access site prior to use mynx control.A non-sterile ¿mynx control vcd 5f¿ involved in the reported complaint was returned for investigation.Visual inspection of the received device showed that both button 1 and button 2 were not depressed.The syringe was received connected to the device and the stopcock was observed opened.The procedural sheath was not received for evaluation.In addition, the balloon was found fully deflated.Additionally, the sealant was noted swollen due as it was exposed to blood and was found partially exposed from the sealant sleeves, which were observed to have been severely kinked/bent as received.However, no cracks were observed on the sealant sleeves.Per functional analysis, an insertion/withdrawal test could not be performed on the returned device due to the severely kinked/bent sealant sleeve assembly and the swollen condition of the sealant exposed to blood.The involved procedural sheath was not returned; therefore, a physical evaluation to determine whether there was damage to the procedural sheath that could have contributed to the reported complaint could not be made.A simulated deployment test was performed on the returned device per the mynx control ifu, button 1 was able to be fully depressed and locked in place with some resistance felt.It was revealed that the sealant was exposed to blood, which caused the resistance felt when attempted to depress the button 1.Button #2 was able to be fully depressed, and no issues were noted with respect to button 2.Per microscopic analysis, visual inspection at high magnification showed evidence that the sealant was found partially exposed from the sealant sleeves due to the observed severely kinked/bent condition with no cracks on it.The reported event of ¿mynx control system-impeded¿ was confirmed through analysis of the returned device since the insertion/withdrawal test could not be executed due to the kinked/bent sealant sleeves and swollen sealant.Additionally, a condition was noted of ¿mynx control system-deployment difficulty-premature¿ due to the partially exposed sealant from the kinked/bent sealant sleeves.The exact cause of the observed condition could not be conclusively determined during analysis.Based on the information available for review and product analysis, it is difficult to determine what factors may have contributed to the issue experienced.However, procedural/handling factors (such as excessive force), and/or the condition of the sheath (which was not returned; although access site had mild pvd/calcium) possibly contributed to the kinked/bent condition of the sealant sleeves, the impedance experienced during insertion, and the subsequent premature exposure of the sealant.It should be noted that the mynx control device is manufactured with a slit at the end of the catheter cartridge tubing.The outer sleeve is assembled with 2 side slit overlapping outer sleeves.The sealant is placed right under the outer sleeve assembly and is protected from exposing prematurely.The slits on the outer sleeve assembly are designed to decrease unsheathing force and increase deployment reliability.Refer to the diagram of the mynx control vcd within the ifu displaying the sealant sleeve with slit.If the outer sleeve is damaged/kinked during prepping phase and/or insertion into sheath, that could cause the sealant to be exposed/swollen prematurely and/or obstruct the device path and prevent the device from being inserted into the procedural sheath.As warned in the ifu, which is not intended as a mitigation, ¿do not use if components or packaging appear to be damaged or defective or if any portion of the packaging has been previously opened.¿ additionally, the ifu states ¿step 1: position balloon, insert the mynx control vcd into the procedural sheath through the sheath valve.Advance the catheter until the sheath catch nears the hub of the sheath.Rotate the sheath catch as needed to hook onto the side port of the procedural sheath.¿ neither the product analysis, nor the information available for review suggest that the reported failures could be related to the design or manufacturing process of the unit.Therefore, no corrective/preventative actions will be taken at this time.
|